Preclinical GPS — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Preclinical GPS operates at the intersection of AI/ML and drug development services, offering a hybrid model of software and hands-on scientific project management for preclinical studies. The company boasts a significant track record, claiming completion of over 1,400 studies, 45+ IND programs, and contribution to 2 NDAs, indicating deep regulatory experience. Its target market is capital-efficient biotechs that need to outsource complex preclinical strategy and execution. While the website emphasizes service delivery, the company's stated sectors suggest an underlying technology platform aimed at optimizing these services.

AI / Machine LearningDrug Delivery

Technology Platform

AI-powered software for preclinical research optimization and drug development decision support, integrated with hands-on scientific services.

Opportunities

Large and growing market for preclinical outsourcing, especially among virtual biotechs.

Significant potential to disrupt traditional CRO models by integrating AI-driven insights into strategic planning and execution, offering faster and more de-risked development pathways.

Risk Factors

Revenue is tied to a competitive project-based services model with potential volatility.

The core AI technology's value proposition lacks public validation.

Scaling an integrated tech-services hybrid requires exceptional execution and faces competition from large CROs and niche consultants.

Competitive Landscape

Competes with large, full-service CROs (e.g., Charles River, Labcorp, ICON) and smaller niche preclinical consulting firms. Differentiation is claimed through an integrated AI-powered platform and a strategic partnership model, but this is unproven against established players with vast resources and data.

More companies in Digital Health & Biotech SaaS →More companies in United States →